PUBLISHER: Grand View Research | PRODUCT CODE: 1772235
PUBLISHER: Grand View Research | PRODUCT CODE: 1772235
U.S. Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts, 2025 - 2033
Market Size & Trends:
The U.S. minimal residual disease testing market was estimated at USD 873.66 million in 2024 and is projected to grow at a CAGR of 9.38% from 2025 and 2033, driven by the country's rising cancer burden and the healthcare system's growing emphasis on precision medicine.
According to recent projections, about 89,190 people in the U.S. will be diagnosed with lymphoma in 2024, encompassing both Hodgkin and non-Hodgkin types. An estimated 21,050 deaths are anticipated, with non-Hodgkin lymphoma being both more common and deadlier, especially in men. These alarming statistics underscore the urgent demand for highly sensitive, early detection tools like MRD testing. MRD testing enables physicians to detect trace levels of cancer cells that persist after treatment, even when patients appear to be in remission. This technology plays a vital role in identifying patients at high risk of relapses, guiding further therapy, and improving long-term outcomes.
The shift toward value-based care and personalized treatment plans has elevated MRD testing from an optional research tool to a mainstream clinical necessity. As cancer therapies become more targeted and adaptive, the demand for precise disease monitoring tools like MRD testing continues to grow. This trend is especially pronounced in hematologic malignancies, where MRD status is increasingly being used as a surrogate endpoint in clinical trials and real-world treatment protocols.
Recent years have witnessed rapid advancements in next-generation sequencing (NGS) and flow cytometry, making MRD detection more accurate, reproducible, and clinically actionable. FDA-cleared tests such as Adaptive Biotechnologies' clonoSEQ for multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) have set new benchmarks for test sensitivity and adoption. Similarly, Natera's Signatera, a tumor-informed ctDNA-based MRD test, is gaining traction in solid tumor management, including colorectal, breast, and bladder cancers. These assays allow for longitudinal disease tracking, personalized treatment decisions, and the early detection of recurrence-often months before symptoms or imaging changes appear.
U.S. Minimal Residual Disease Testing Market Report Segmentation
This report forecasts revenue growth at regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. minimal residual disease testing market report based on the technology, cancer type, and end use:
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Amplicon-based NGS
- Hybridization Capture-based NGS
- Others
- Others
- Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
- Hematological Malignancy
- Leukemia
- Lymphoma
- Solid Tumors
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Technology Segment
- 1.1.1.2. Cancer Type Segment
- 1.1.1.3. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Primary Sources
- 1.11. List of Abbreviations
Chapter 2. U.S. Minimal Residual Disease Testing Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Technology and Services Snapshots
- 2.3. Cancer Type and End Use Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. U.S. Minimal Residual Disease Testing Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Rising incidence and prevalence of hematological malignancies
- 3.4.2. Technological advancements in diagnostic tools
- 3.4.3. Integration with personalized medicines
- 3.5. Market Restraint Analysis
- 3.5.1. High cost and limited accessibility of advanced MRD technologies
- 3.6. U.S. Minimal Residual Disease Testing Market Analysis Tools
- 3.6.1. Industry Analysis - Porter's
- 3.6.1.1. Supplier Power
- 3.6.1.2. Buyer Power
- 3.6.1.3. Substitution Threat
- 3.6.1.4. Threat of New Entrants
- 3.6.1.5. Competitive Rivalry
- 3.6.2. PESTLE Analysis
- 3.6.2.1. Political Landscape
- 3.6.2.2. Technological Landscape
- 3.6.2.3. Economic Landscape
- 3.6.1. Industry Analysis - Porter's
Chapter 4. U.S. Minimal Residual Disease Testing: Products, Estimates & Trend Analysis
- 4.1. Product Market Share, 2024 & 2033
- 4.2. Segment Dashboard
- 4.3. U.S. Minimal Residual Disease Testing Market, By Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
- 4.4.1. Flow Cytometry
- 4.4.1.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.2. Polymerase Chain Reaction (PCR)
- 4.4.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.3. Next Generation Sequencing (NGS)
- 4.4.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.3.2. Amplicon-based NGS
- 4.4.3.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.3.3. Hybridization Capture-based NGS
- 4.4.3.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.3.4. Others
- 4.4.3.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.4. Others
- 4.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 4.4.1. Flow Cytometry
Chapter 5. U.S. Minimal Residual Disease Testing: Cancer Type Estimates & Trend Analysis
- 5.1. Cancer Type Market Share, 2024 & 2033
- 5.2. Segment Dashboard
- 5.3. U.S. Minimal Residual Disease Testing Market, By Cancer Type Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
- 5.4.1. Hematological Malignancy
- 5.4.1.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.1.2. Leukemia
- 5.4.1.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
- 5.4.1.3. Lymphoma
- 5.4.1.3.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
- 5.4.2. Solid Tumors
- 5.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.1. Hematological Malignancy
Chapter 6. Minimal Residual Disease Testing: End Use Estimates & Trend Analysis
- 6.1. End Use Market Share, 2024 & 2033
- 6.2. Segment Dashboard
- 6.3. Global U.S. Minimal Residual Disease Testing Market, By End Use Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
- 6.4.1. Hospitals and Specialty Clinics
- 6.4.1.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
- 6.4.2. Diagnostic Laboratories
- 6.4.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
- 6.4.3. Academic and Research Institutes
- 6.4.4. Others
- 6.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 6.4.1. Hospitals and Specialty Clinics
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company /Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of Key Distributors and Channel Partners
- 7.3.2. Key Customers
- 7.3.3. Key Company Market Share Analysis, 2024
- 7.3.4. Twist Bioscience
- 7.3.4.1. Overview
- 7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.4.3. Product Benchmarking
- 7.3.4.4. Strategic Initiatives
- 7.3.5. Thermo Fisher Scientific, Inc
- 7.3.5.1. Overview
- 7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.5.3. Product Benchmarking
- 7.3.5.4. Strategic Initiatives
- 7.3.6. Illumina, Inc.
- 7.3.6.1. Overview
- 7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.6.3. Product Benchmarking
- 7.3.6.4. Strategic Initiatives
- 7.3.7. QIAGEN
- 7.3.7.1. Overview
- 7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.7.3. Product Benchmarking
- 7.3.7.4. Strategic Initiatives
- 7.3.8. Adaptive Biotechnologies
- 7.3.8.1. Overview
- 7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.8.3. Product Benchmarking
- 7.3.8.4. Strategic Initiatives
- 7.3.9. Natera, Inc.
- 7.3.9.1. Overview
- 7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.9.3. Product Benchmarking
- 7.3.9.4. Strategic Initiatives
- 7.3.10. Guardant Health
- 7.3.10.1. Overview
- 7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.10.3. Product Benchmarking
- 7.3.10.4. Strategic Initiatives
- 7.3.11. Foresight Diagnostics, Inc.
- 7.3.11.1. Overview
- 7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.11.3. Product Benchmarking
- 7.3.11.4. Strategic Initiatives
- 7.3.12. NeoGenomics, Inc.
- 7.3.12.1. Overview
- 7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.12.3. Product Benchmarking
- 7.3.12.4. Strategic Initiatives
- 7.3.13. Hoffmann-La Roche Ltd.
- 7.3.13.1. Overview
- 7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.13.3. Product Benchmarking
- 7.3.13.4. Strategic Initiatives
- 7.3.14. SOPHiA GENETICS
- 7.3.14.1. Overview
- 7.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 7.3.14.3. Product Benchmarking
- 7.3.14.4. Strategic Initiatives
List of Tables
- Table 1. List of key distributors and channel partners
- Table 2. List of key emerging companies'/technology disruptors/innovators
- Table 3. U.S. Minimal Residual Disease Testing Market, By Product, 2021 - 2033 (USD Million)
- Table 4. U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2021 - 2033 (USD Million)
- Table 5. U.S. Minimal Residual Disease Testing Market, By End Use, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information Procurement
- Fig. 3 Primary Research Pattern
- Fig. 4 Market Research Approaches
- Fig. 5 Value Chain-Based Sizing & Forecasting
- Fig. 6 Market Formulation & Validation
- Fig. 7 U.S. Minimal Residual Disease Testing Market Segmentation
- Fig. 8 Market Snapshot, 2024
- Fig. 9 Market Trends & Outlook
- Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
- Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
- Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
- Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
- Fig. 14 Porter's Five Forces Analysis
- Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2024
- Fig. 16 U.S. Minimal Residual Disease Testing Market: Product Movement Analysis
- Fig. 17 U.S. Minimal Residual Disease Testing Market: Product Outlook and Key Takeaways
- Fig. 18 Flow Cytometry
- Fig. 19 Polymerase Chain Reaction (PCR)
- Fig. 20 Next Generation Sequencing (NGS)
- Fig. 21 Others Market Estimates and Forecast, 2021 - 2033
- Fig. 22 Amplicon-based NGS Market Estimates and Forecast, 2021 - 2033
- Fig. 23 Hybridization Capture-based NGS Market Estimates and Forecast, 2021 - 2033
- Fig. 24 Other Estimates and Forecast, 2021 - 2033
- Fig. 25 U.S. Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
- Fig. 26 U.S. Minimal Residual Disease Testing Market: Cancer Type Outlook and Key Takeaways
- Fig. 27 Hematological Malignancy Market Estimates and Forecasts, 2021 - 2033
- Fig. 28 Solid Tumors Market Estimates and Forecasts, 2021 - 2033
- Fig. 29 Blood & Blood-based Products Market Estimates and Forecasts,2021 - 2033
- Fig. 30 Leukemia Market Estimates and Forecasts,2021 - 2033
- Fig. 31 Lymphoma Market Estimates and Forecasts,2021 - 2033
- Fig. 32 U.S. Minimal Residual Disease Testing Market: End Use Movement Analysis
- Fig. 33 U.S. Minimal Residual Disease Testing Market: End Use Outlook and Key Takeaways
- Fig. 34 Hospitals and Specialty Clinics Market Estimates and Forecasts, 2021 - 2033
- Fig. 35 Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033
- Fig. 36 Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033
- Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033
